Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Novartis to buy French...

    Novartis to buy French cancer specialist AAA for $3.9 billion

    Written by supriya kashyap kashyap Published On 2017-11-03T13:21:27+05:30  |  Updated On 3 Nov 2017 1:21 PM IST
    Novartis to buy French cancer specialist AAA for $3.9 billion

    Zurich: Novartis has agreed to buy French-based Advanced Accelerator Applications (AAA) for $3.9 billion, giving it a platform in radiopharmaceuticals and access to a new therapy for the kind of cancer that killed Steve Jobs.


    The deal further strengthens the Swiss drugmaker's oncology business, already boosted by the 2015 acquisition of GlaxoSmithKline's marketed cancer drugs and August's approval of a ground-breaking gene-modifying leukaemia treatment.


    The cash offer of $41 per ordinary share and $82 per American depositary share represents a 47 percent premium to AAA's price before media reports on Sept. 27 that Novartis was interested, the two companies said on Monday.


    The ADS, which closed on Friday at $72.91 and were priced at only $16 when they listed two years ago, traded at $80 in U.S. premarket dealings.


    The transaction, which Novartis is to finance using debt, will reap AAA founder and 11 percent owner Stefano Buono more than $420 million.


    The move fits with Novartis Chief Executive Joe Jimenez's strategy of pursuing bolt-on deals worth up to around $5 billion rather than seeking out larger targets.


    With AAA, Novartis gets technology that deploys trace amounts of radioactive compounds to not only create images of organs and lesions to diagnose diseases but which can also be used to fight cancer.


    AAA's flagship product, Lutathera, won European Union backing in late September against rare gastroenteropancreatic neuroendocrine tumours, the likes of which killed Jobs, Apple's founder, in 2011.


    "Novartis has a strong legacy in the development and commercialisation of medicines for neuroendocrine tumours," said Bruno Strigini, head of Novartis Oncology. "With Lutathera we can build on this legacy."


    PEAK SALES


    Lutathera, which has also been submitted to the U.S. Food and Drug Administration, harnesses a molecule not only to diagnose cancer but also to deliver treatment by hitting tumours with high-energy electrons.


    In trials, it demonstrated a 79 percent risk reduction versus Novartis's $1.6 billion-per-year drug Sandostatin against neuroendocrine tumours. Now, Novartis will likely replace patent-expired Sandostatin with its new drug, said Baader Helvea analyst Bruno Bulic.


    "We see the more sophisticated technology to Lutathera commanding a premium price to Sandostatin and estimate peak sales potential at $2 billion," Bulic wrote in a research note.


    Analysts from Vontobel said the $3.9 billion price "appears expensive" given AAA spun off from Europe's physics research centre CERN 15 years ago and listed on Nasdaq had sales of just $78 million in the first half of 2017.


    Novartis shares were little changed at 1115 GMT.


    AAA founder Buono said the deal with the world's biggest maker of prescription drugs would not only support Lutathera's launch but also accelerate development of its other therapies.


    The Italian-born former CERN physicist steadily took on investors and built up manufacturing capacity while making small acquisitions. AAA went public in a 2015 IPO.


    Its other biggest shareholders are Fidelity with 9.1 percent and HBM Healthcare Investments run by former Roche finance chief Henri B. Meier. PJT Partners served as financial adviser and Shearman & Sterling as legal adviser for Novartis. Jefferies LLC was financial adviser to AAA, with Davis Polk & Wardwell LLP serving as legal counsel.


    (Additional reporting by Ben Hirschler in London; Editing by Michael Shields and Keith Weir)

    AAAAdvanced Accelerator ApplicationBruno Striginicancercancer drugGlaxoSmithKlineJoe Jimenez'sleukaemiaNovartisradiopharmaceuticalsSwiss drugmaker
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok